179 related articles for article (PubMed ID: 26403354)
1. 2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.
Gohlke BO; Overkamp T; Richter A; Richter A; Daniel PT; Gillissen B; Preissner R
BMC Bioinformatics; 2015 Sep; 16():308. PubMed ID: 26403354
[TBL] [Abstract][Full Text] [Related]
2. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
3. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
[TBL] [Abstract][Full Text] [Related]
4. 2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors.
Nilov DK; Yashina KI; Gushchina IV; Zakharenko AL; Sukhanova MV; Lavrik OI; Švedas VK
Biochemistry (Mosc); 2018 Feb; 83(2):152-158. PubMed ID: 29618301
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
Zeng H; Zhang H; Jang F; Zhao L; Zhang J
Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
[TBL] [Abstract][Full Text] [Related]
6. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Wang H; Ren B; Liu Y; Jiang B; Guo Y; Wei M; Luo L; Kuang X; Qiu M; Lv L; Xu H; Qi R; Yan H; Xu D; Wang Z; Huo CX; Zhu Y; Zhao Y; Wu Y; Qin Z; Su D; Tang T; Wang F; Sun X; Feng Y; Peng H; Wang X; Gao Y; Liu Y; Gong W; Yu F; Liu X; Wang L; Zhou C
J Med Chem; 2020 Dec; 63(24):15541-15563. PubMed ID: 33264017
[TBL] [Abstract][Full Text] [Related]
8. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
[TBL] [Abstract][Full Text] [Related]
9. Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
Mey L; Hörmann M; Schleicher N; Reuter P; Dönges S; Kinscherf R; Gassmann M; Gerriets T; Al-Fakhri N
Neurobiol Dis; 2013 Nov; 59():111-25. PubMed ID: 23816753
[TBL] [Abstract][Full Text] [Related]
10. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
11. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
[TBL] [Abstract][Full Text] [Related]
12. The kinase polypharmacology landscape of clinical PARP inhibitors.
Antolin AA; Ameratunga M; Banerji U; Clarke PA; Workman P; Al-Lazikani B
Sci Rep; 2020 Feb; 10(1):2585. PubMed ID: 32066817
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel PARP-1 inhibitors by structure-based virtual screening.
Hannigan K; Kulkarni SS; Bdzhola VG; Golub AG; Yarmoluk SM; Talele TT
Bioorg Med Chem Lett; 2013 Nov; 23(21):5790-4. PubMed ID: 24074844
[TBL] [Abstract][Full Text] [Related]
14. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
Cao R
J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
[TBL] [Abstract][Full Text] [Related]
15. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
[No Abstract] [Full Text] [Related]
17. Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
Goodfellow E; Senhaji Mouhri Z; Williams C; Jean-Claude BJ
Bioorg Med Chem Lett; 2017 Feb; 27(3):688-694. PubMed ID: 28003142
[TBL] [Abstract][Full Text] [Related]
18. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
Johannes JW; Almeida L; Daly K; Ferguson AD; Grosskurth SE; Guan H; Howard T; Ioannidis S; Kazmirski S; Lamb ML; Larsen NA; Lyne PD; Mikule K; Ogoe C; Peng B; Petteruti P; Read JA; Su N; Sylvester M; Throner S; Wang W; Wang X; Wu J; Ye Q; Yu Y; Zheng X; Scott DA
Bioorg Med Chem Lett; 2015 Dec; 25(24):5743-7. PubMed ID: 26546219
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
20. High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection.
Kotova E; Tulin AV
Methods Mol Biol; 2017; 1608():299-312. PubMed ID: 28695517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
